Treos Bio

Treos Bio is pioneering a novel approach to active cancer immunotherapy with its PEPI technology platform, which uses computationally designed peptides that bind to multiple HLA types to trigger strong anti-tumor immune responses. The company's lead candidate, PolyPEPI1018 for colorectal cancer, has shown promising immunological and clinical signals in multiple trials. With a focus on creating accessible, off-the-shelf treatments, Treos aims to transform cancer care by making immunotherapies effective for broader patient groups and combinable with other standard therapies.

PEPI (Promiscuous Epitope) technology: A computational platform that designs peptide sequences which bind to multiple HLA molecules within an individual to stimulate strong, polyclonal T-cell responses against tumor-associated antigens. It utilizes a proprietary tumor database for antigen selection and enables the development of off-the-shelf immunotherapies with a companion diagnostic based on HLA genotyping.

Treos Bio competes in the broad cancer immunotherapy space, which includes checkpoint inhibitors, personalized neoantigen vaccines, and cellular therapies. Its primary differentiation is its off-the-shelf, multi-HLA targeting peptide approach aimed at cold tumors. Direct competitors include other companies developing off-the-shelf cancer vaccines (e.g., using shared tumor antigens) and those targeting MSS colorectal cancer specifically.